FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
28-residue immunomodulatory thymic peptide
Overview
Thymosin Alpha-1 (Tα1, thymalfasin) is a 28-amino-acid N-terminally acetylated peptide derived from prothymosin alpha, originally isolated from thymic tissue. It is one of the most-studied immunomodulatory peptides, researched for its effects on T-cell maturation, dendritic-cell signalling, and innate/adaptive immune balance, with the synthetic version marketed as thymalfasin in several countries. Vialdyne releases lyophilised Thymosin Alpha-1 at ≥99.0% HPLC main-peak, with a batch COA covering RP-HPLC purity, peptide-content assay, ESI-MS identity (theoretical vs observed), water (Karl Fischer), counter-ion, residual solvents, endotoxin, and microbial limits. The N-terminal acetylation is confirmed by mass spec on the released lot.
Applications & buyer fit
Buyers in this category are research labs studying immune-modulation, cytokine signaling, and antimicrobial activity. The defining QC requirement is bacterial-endotoxin control: many of the downstream assays (NF-κB reporters, macrophage activation panels, neutrophil-priming readouts) are themselves activated by endotoxin contamination, so a clean LAL on the specific batch is a precondition rather than a nice-to-have. LL-37 and related cationic antimicrobial peptides additionally benefit from low-bind plasticware during dilution.
Sourced for
Buyer fit
Documentation that ships
Procurement note: A clean LAL result on the specific lot is the defining requirement, since many downstream assays are themselves activated by endotoxin.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for Thymosin Alpha-1 (Tα1), every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
Browse all published COAsRegulatory note
Research-use-only reference material; the synthetic peptide (thymalfasin) is an approved medicine in some countries but is supplied here strictly for research, not for human or veterinary use.
Frequently asked questions
Thymosin Alpha-1 is a 28-residue N-terminally acetylated peptide cleaved from prothymosin alpha, first isolated from thymic tissue and now produced synthetically. The acetylated N-terminus is part of its defining identity and is confirmed by mass spec on every Vialdyne lot. It is studied as an immunomodulator acting on T-cell maturation and dendritic-cell signalling; the synthetic form is known internationally as thymalfasin.
Because the molecule is a 28-mer with a defining N-terminal acetyl group, the released-batch COA pairs HPLC purity (≥99.0%) with ESI-MS identity, reporting theoretical versus observed mass (3108.30 g/mol) so the acetylation and full mass are confirmed, not inferred. Peptide-content assay, counter-ion, water, endotoxin, and microbial limits complete the release file; full sequence confirmation is available as an add-on.
Related peptides
